Murtough, Stephen;
(2026)
ACKR1 genetic testing should be offered before starting clozapine treatment.
Nature Mental Health
10.1038/s44220-025-00554-9.
(In press).
Preview |
Text
Murtough_ACKR1 genetic testing should be offered before starting clozapine treatment Murtough et al accepted manuscript at Nature Mental Health.pdf Download (646kB) | Preview |
Abstract
Clozapine is the most effective therapy for treatment-resistant schizophrenia, although it can cause neutropenia. In many countries, neutrophil count monitoring is mandatory for people taking clozapine, who must remain above a minimum threshold to start and continue treatment. Some people have low neutrophil counts without increased infection risk, caused by a homozygous variant in ACKR1 and termed ACKR1/DARC-associated neutropenia (ADAN). When ADAN is confirmed, reduced neutrophil count thresholds are applied to allow people to start and continue clozapine. However, ADAN diagnoses are often missed, resulting in reduced access to clozapine and unnecessary discontinuation. We review the evidence for ACKR1 genetic testing to rapidly identify ADAN in people taking clozapine. With multidisciplinary input, we recommend internationally relevant test eligibility criteria, comprising pre-emptive and reactive testing strategies, and we conduct a health economic analysis, estimating total cost savings between £42,732 and £727,990 for the UK healthcare system during the first year of testing. Finally, we propose how to integrate these criteria into clinical practice to enable equitable access to clozapine.
Archive Staff Only
 |
View Item |
